307 related articles for article (PubMed ID: 16440331)
1. Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility.
Marcelli M; Stenoien DL; Szafran AT; Simeoni S; Agoulnik IU; Weigel NL; Moran T; Mikic I; Price JH; Mancini MA
J Cell Biochem; 2006 Jul; 98(4):770-88. PubMed ID: 16440331
[TBL] [Abstract][Full Text] [Related]
2. Antiandrogens prevent stable DNA-binding of the androgen receptor.
Farla P; Hersmus R; Trapman J; Houtsmuller AB
J Cell Sci; 2005 Sep; 118(Pt 18):4187-98. PubMed ID: 16141232
[TBL] [Abstract][Full Text] [Related]
3. Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells.
Tyagi RK; Lavrovsky Y; Ahn SC; Song CS; Chatterjee B; Roy AK
Mol Endocrinol; 2000 Aug; 14(8):1162-74. PubMed ID: 10935541
[TBL] [Abstract][Full Text] [Related]
4. Differential modulation of androgen receptor transcriptional activity by the nuclear receptor co-repressor (N-CoR).
Berrevoets CA; Umar A; Trapman J; Brinkmann AO
Biochem J; 2004 May; 379(Pt 3):731-8. PubMed ID: 14744261
[TBL] [Abstract][Full Text] [Related]
5. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.
Ozers MS; Marks BD; Gowda K; Kupcho KR; Ervin KM; De Rosier T; Qadir N; Eliason HC; Riddle SM; Shekhani MS
Biochemistry; 2007 Jan; 46(3):683-95. PubMed ID: 17223690
[TBL] [Abstract][Full Text] [Related]
6. The androgen receptor ligand-binding domain stabilizes DNA binding in living cells.
Farla P; Hersmus R; Geverts B; Mari PO; Nigg AL; Dubbink HJ; Trapman J; Houtsmuller AB
J Struct Biol; 2004 Jul; 147(1):50-61. PubMed ID: 15109605
[TBL] [Abstract][Full Text] [Related]
7. A differential ligand-mediated response of green fluorescent protein-tagged androgen receptor in living prostate cancer and non-prostate cancer cell lines.
Nakauchi H; Matsuda K; Ochiai I; Kawauchi A; Mizutani Y; Miki T; Kawata M
J Histochem Cytochem; 2007 Jun; 55(6):535-44. PubMed ID: 17312014
[TBL] [Abstract][Full Text] [Related]
8. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
Hodgson MC; Astapova I; Hollenberg AN; Balk SP
Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
Whitaker HC; Hanrahan S; Totty N; Gamble SC; Waxman J; Cato AC; Hurst HC; Bevan CL
Clin Cancer Res; 2004 Nov; 10(21):7392-401. PubMed ID: 15534116
[TBL] [Abstract][Full Text] [Related]
10. Studies of targeting and intracellular trafficking of an anti-androgen doxorubicin-formaldehyde conjugate in PC-3 prostate cancer cells bearing androgen receptor-GFP chimera.
Cogan PS; Koch TH
J Med Chem; 2004 Nov; 47(23):5690-9. PubMed ID: 15509168
[TBL] [Abstract][Full Text] [Related]
11. Antiandrogenic activity of norgestimate in a human androgen-dependent stable-transfected cell line.
Paris F; Rabeolina F; Balaguer P; Bacquet A; Sultan C
Gynecol Endocrinol; 2007 Apr; 23(4):193-7. PubMed ID: 17505938
[TBL] [Abstract][Full Text] [Related]
12. Partial agonist/antagonist properties of androstenedione and 4-androsten-3beta,17beta-diol.
Chen F; Knecht K; Leu C; Rutledge SJ; Scafonas A; Gambone C; Vogel R; Zhang H; Kasparcova V; Bai C; Harada S; Schmidt A; Reszka A; Freedman L
J Steroid Biochem Mol Biol; 2004 Aug; 91(4-5):247-57. PubMed ID: 15336702
[TBL] [Abstract][Full Text] [Related]
13. Discovery and mechanistic characterization of a novel selective nuclear androgen receptor exporter for the treatment of prostate cancer.
Narayanan R; Yepuru M; Szafran AT; Szwarc M; Bohl CE; Young NL; Miller DD; Mancini MA; Dalton JT
Cancer Res; 2010 Jan; 70(2):842-51. PubMed ID: 20068182
[TBL] [Abstract][Full Text] [Related]
14. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
[TBL] [Abstract][Full Text] [Related]
15. Study of the impact of the T877A mutation on ligand-induced helix-12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens.
Zhou J; Liu B; Geng G; Wu JH
Proteins; 2010 Feb; 78(3):623-37. PubMed ID: 19787772
[TBL] [Abstract][Full Text] [Related]
16. Role of the promyelocytic leukemia body in the dynamic interaction between the androgen receptor and steroid receptor coactivator-1 in living cells.
Rivera OJ; Song CS; Centonze VE; Lechleiter JD; Chatterjee B; Roy AK
Mol Endocrinol; 2003 Jan; 17(1):128-40. PubMed ID: 12511612
[TBL] [Abstract][Full Text] [Related]
17. Stabilization of androgen receptor protein is induced by agonist, not by antagonists.
Furutani T; Watanabe T; Tanimoto K; Hashimoto T; Koutoku H; Kudoh M; Shimizu Y; Kato S; Shikama H
Biochem Biophys Res Commun; 2002 Jun; 294(4):779-84. PubMed ID: 12061774
[TBL] [Abstract][Full Text] [Related]
18. Impaired helix 12 dynamics due to proline 892 substitutions in the androgen receptor are associated with complete androgen insensitivity.
Elhaji YA; Stoica I; Dennis S; Purisima EO; Lumbroso R; Beitel LK; Trifiro MA
Hum Mol Genet; 2006 Mar; 15(6):921-31. PubMed ID: 16449235
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
20. Green fluorescent protein-tagging reduces the nucleocytoplasmic shuttling specifically of unphosphorylated STAT1.
Meyer T; Begitt A; Vinkemeier U
FEBS J; 2007 Feb; 274(3):815-26. PubMed ID: 17288561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
